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Body Cell Mass (BCM) is a sum of all metabolically active cells of the
body. Aim of the study was to compare BCM with other nutritional and
inﬂammatory markers in patients with chronic kidney disease (CKD) stage
4-5 (NKF) without dialysis treatment and in hemodialysis patients(HD).
We included 45 adult patients with CKD and eGFRo30 ml/min not treated
with dialysis (26 male, age: 59,7716,8) and 39 adults treated with HD
three times a week, for more than three months (26 male, 5 diabetics, age:
59,8 716). Body composition was measured using multifrequency
biopimpedance spectroscopy: Body Composition Monitor - FMC. We used
BCM index (BCMI) deﬁned as BCM divided by height to the power of 2. To
measure hand grip strength (HGS) we used dynamometr Jamar. In statistics
analysis we used Pearson correlations (SPSS v18). Predialysis group: BCMI:
7,1 71,6 kg/m2, Lean Tissue Index (LTI): 12,9 72,4 kg/m2, Fat Tissue Index
(FTI): 14,7 75,4 kg/m2, BMI: 28,2 75 kg/m2, serum creatinine level (SCr):
3,9 72,1 mg/dl, eGFR: 18,3 77,0034 ml/min/1,73 m2, albumin (SA): 3,9
70,3 g/dl, prealbumin (PA): 32,8 78,8 mg/dl, CRP: 0,5 70,3 mg/dl. A
positive correlation was found with BCMI and HGS (r ¼ 0,55; p¼0,001), PA
(r ¼ 0,41; p¼0,004) and SCr (r ¼0,37; p¼0,012). A negative correlation
was found between BCMI and age (r ¼ -0,48; p¼0,006), CRP (r ¼ -0,33;
p¼0,028). We do not observed correlation with BMI and SA. HD group:
BCMI: 6,471,7 kg/m2, LTI: 12,172,3 kg/m2, FTI: 12 76 kg/m2, BMI: 24,8
74,8, SCr: 8,9 72,6 mg/dl, TP: 6,7 70,6 g/dl, SA: 3,9 70,47 g/dl, PA 33,8
711,4 g/dl, CRP: 1,1 71,4 mg/dl. A positive, signiﬁcant correlation was
found between BCMI and HGS (r ¼ 0,47; p¼0,003). A negative correlation
was found with BCMI and age (r ¼ -0,55; p¼0,0005) and with CRP (r ¼ -
0,31), but not statistically signiﬁcant. We do not observed correlation
between BCMI and BMI, SCr, TP, SA, PA, hemodialysis vintage, Kt/V.
Assessment of body compartments is important tool in estimation
nutritional status in patients with stage IV-V CKD and hemodialysis
patients. Analysis of body composition in association with other markers
worth to be studied, especially in larger groups of patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.534211
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The aim of the study was to compare: Body Cell Mass Index (BCMI), Lean
Tissue Index (LTI), Fat Tissue Index (FTI) measured by multifrequency
bioimpedance spectroscopy (Body Composition Monitor-FMC) according to
age and gender in patients with CKD stage 4-5 (NKF) without dialysis
treatment and in hemodialysis patients (HD). We included 45 adult
patients (pts) with CKD and eGFR o 30 ml/min not treated with dialysis -
predialysis group (26 male, age: 59,7 716,8) and 39 adults treated with
HD three times a week, for more than three months (26 male, age: 59,8
716,0). We deﬁned BCMI as Body Cell Mass divided by square body height
and analogically LTI and FTI (kg/m2). In statistics analysis we used
t-student test (SPSS v18).Predialysis BCMI LTI FTI BMIr 59 y 8,0 71,6 14,4 72,4 12,5 75,4 27,7 75,5
Z 60 y 6,4 71,4 11,9 72,0 15,8 75,0 28,5 74,8
Females 6,0 71,2 11,3 71,8 17,2 76,3 28,5 76,1
Male 7,9 71,5 14,2 72,1 12,7 73,5 28,0 74,0In predialysis pts mean BCMI and LTI were signiﬁcantly lower in females
and older whereas BMI did not differ signiﬁcantly. Mean FTI was
signiﬁcantly higher in females (for all p o 0,05).Hemodial. BCMI LTI FTI BMIr 59 y 7,2 71,7 13,2 72,5 10,3 77,0 24,0 75,3
Z 60 y 5,8 71,4 11,3 71,9 13,3 74,9 25,4 74,4Females 6,4 71,4 12,0 71,9 11,5 74,8 24,0 74,4
Males 6,4 71,8 12,2 72,6 12,2 76,6 25,1 75,0In hemodialysis patients no signiﬁcant differences was observed in
females and males in all BCMI, LTI, FTI and BMI. BCMI, LTI were
signiﬁcantly lower in older pts whereas BMI did not differ signiﬁcantly (for
all p o 0,05). In both groups BCMI and LTI decline in patients over 60 years
whereas only in hemodialysis patients they do not differ in females and
males. Analysis of body composition in patients with CKD is worth to be
studied in large group of patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.535212
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Liraglutide (Lira), a glucagon-like peptide-1 receptor agonist, can be
administered to diabetic patients with renal failure without dose
reduction, but experience with the use of Lira in these patients is limited.
This study was designed to examine the effects of 6-month Lira
administration on glucose metabolism, body mass index (BMI), and renal
function in 18 patients with diabetic nephropathy (eGFR o60 ml/min).
The study included 18 patients with diabetic nephropathy who were on
insulin/oral hypoglycemic medications (6 men, 12 women; average age, 60
years; HbA1c, 8.4%; BMI, 29.4 7 8.2; duration of diabetes, 12 years; eGFR,
55.2 7 6.3 ml/min/1.73 m2). Lira was given either in combination or as
monotherapy. After 6 months of Lira treatment, changes in HbA1c levels,
casual blood glucose levels, BMI, and eGFR were examined.
The average HbA1c and casual blood glucose levels were signiﬁcantly
decreased after 6-month Lira administration (HbA1c before administration
8.4%, 7.9% at Month 1, 7.4% at Month 2, 7.1% at Month 3, 7.1% at Month 6; p
o 0.01 respectively, Paired T test). There were, however, no signiﬁcant
changes in renal function.
In conclusion, these results suggest that the administration of Lira in
patients with diabetic nephropathy may improve glucose metabolism and
reduce BMI without affecting renal function or albuminuria in the
short term.
http://dx.doi.org/10.1016/j.krcp.2012.04.536213
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Fetuin-A is a calciﬁcation inhibitor, negative acute phase response
marker and cardiovascular mortality predictor in hemodialysis patients.
Low levels of fetuin-A are associated with malnutrition, inﬂammation,
decreased bone mass density, low-turnover bone and use of high calcium
concentration dialysate. Hemodialysis procedure (HD) has been shown to
decrease fetuin-A levels by 20%, probably due to HD-induced inﬂammation
or acute changes in calcium metabolism. The aim of our study was to
investigate effects of HD on serum fetuin-A levels. Forty clinically and
hemodynamically stable hemodialysis patients (21 females, 68 (38-85)
years) underwent routine bicarbonate hemodialysis or hemodiaﬁltration
with polysulfone dialyzer. On consecutive HD dialysis solution with
different calcium concentration with/without citric acid was used to assess
inﬂuence of calcium shifts and parathyroid activity on fetuin-A changes
during HD. All other parameters of HD were kept constant. Serum fetuin-A,
calcium, phosphorus, iPTH, CRP and other biochemical parameters were
measured before and after each HD. Our data show that predialysis serum
fetuin-A levels have positive correlation with iPTH levels (po0.05) and
